Publicaciones en colaboración con investigadores/as de Virginia Commonwealth University (13)

2024

  1. Fibrinolytic Agents in Thromboembolic Diseases: Historical Perspectives and Approved Indications

    Seminars in Thrombosis and Hemostasis, Vol. 50, Núm. 5, pp. 773-789

  2. Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease

    Nature Reviews Cardiology, Vol. 21, Núm. 8, pp. 574-592

  3. When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review

    Journal of the American College of Cardiology, Vol. 83, Núm. 3, pp. 444-465

2023

  1. Atorvastatin versus Placebo in ICU Patients with COVID-19: Ninety-day Results of the INSPIRATION-S Trial

    Thrombosis and haemostasis, Vol. 123, Núm. 7, pp. 723-733

2022

  1. Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial

    The BMJ, Vol. 376

  2. Durable functional limitation in patients with coronavirus disease-2019 admitted to intensive care and the effect of intermediate-dose vs standard-dose anticoagulation on functional outcomes

    European Journal of Internal Medicine, Vol. 103, pp. 76-83

  3. Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review

    JAMA Cardiology, Vol. 7, Núm. 7, pp. 747-759

2021

  1. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality among Patients with COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial

    JAMA - Journal of the American Medical Association, Vol. 325, Núm. 16, pp. 1620-1630

  2. Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial

    Thrombosis and Haemostasis, Vol. 122, Núm. 1, pp. 131-141

  3. Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review

    Journal of the American College of Cardiology, Vol. 78, Núm. 16, pp. 1635-1654

  4. Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review

    Journal of the American College of Cardiology, Vol. 77, Núm. 15, pp. 1903-1921

  5. Right ventricle assessment in patients with pulmonary embolism at low risk for death based on clinical models: an individual patient data meta-analysis

    European heart journal, Vol. 42, Núm. 33, pp. 3190-3199

2016

  1. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report

    Chest, Vol. 149, Núm. 2, pp. 315-352